Ep. 181 - Highlights from ASCO
BioCentury This Week
00:00
Alchias: A Single Asset Company With Potential
Alchias has more trials going in various stages of star guard disease. The one readout they have is in the most advanced patients, but now there's an intermediate patient study that is ongoing with 80 patients. And there's also a phase three due to readout in a broader indication, which is geographic atrophy associated with AMD. So we'll see where this takes them, but we obviously will be anticipating more news from them in the next year or so.
Transcript
Play full episode
